REGN Q4 2023 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.4B+0.6% YoY

Gross Profit

$2.8B81.7% margin

Operating Income

$1.1B30.6% margin

Net Income

$1.2B33.8% margin

EPS (Diluted)

$10.19

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$776M

Stock-Based Comp.

$240M

Balance Sheet

Total Assets

$33.1B

Total Liabilities

$7.1B

Stockholders' Equity

$26.0B

Cash & Equivalents

$2.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.4B	$3.4B	+0.6%
Gross Profit	$2.8B	$2.9B	-3.5%
Operating Income	$1.1B	$1.3B	-20.1%
Net Income	$1.2B	$1.2B	-3.1%

Revenue Segments

Product

$1.9B54%

Collaboration Revenue

$1.4B40%

Product and Service, Other

$213M6%